AHSG

Across TCGA pan-cancer cohorts, AHSG Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AHSG data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher AHSG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AHSG expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, LUAD, and KIRC are the cancer types where AHSG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.033	0.784	<.001	24	view →
LUAD	DFS	Median	IV	0.045	0.717	<.001	18	view →
KIRC	OS	Median	All	0.152	0.874	<.001	12	view →
SCLC	OS	Median	All	0.132	0.796	.001	9	view →
SKCM	DFS	Median	III,IV	0.906	0.484	.011	9	view →
HNSC	OS	Median	All	0.319	0.687	.039	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AHSG–LIHC (OS)

Open the LIHC breakdown →